Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas

Bone Marrow Transplantation volume 39, pages 471–476 (2007)Cite this article

Abstract

The treatment of small-round-cell tumors (SRCT) in adult patients remains a challenge to clinicians. In the present study, we analyzed the feasibility and efficacy of high-dose chemotherapy (HDCT) followed by autologous peripheral blood stem-cell rescue as a consolidation therapy exclusively for patients with good disease control through a single regimen of induction chemotherapy and local therapy. Twenty-one patients (12 females, median age 22.0 years) were analyzed, including seven cases with rhabdomyosarcoma (RMS) and 14 cases with Ewing's family tumors (EFT). Overall, survival was 46% and failure-free survival (FFS) was 33% at 3 years. Patients with EFT had better FFS than those with RMS, with an estimated 3-year FFS of 50% (P<0.01). There was a single case of possible treatment-related death and two cases of secondary malignancies. This study cannot conclusively determine the beneficial effects of HDCT for improving treatment outcomes in adult SRCTs due to the small number of subjects. However, study findings suggest that a subgroup of patients with EFT may obtain prolonged survival benefits from this therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM et al. The Ewing family of tumors: a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331: 294–299.

    Article  CAS  Google Scholar 

  2. Pisick E, Skarin AT, Salgia R . Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. Anticancer Res 2003; 23: 3379–3396.

    PubMed  Google Scholar 

  3. Nesbit Jr ME, Gehan EA, Burgert Jr EO, Vietti TJ, Cangir A, Tefft M et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol 1990; 8: 1664–1674.

    Article  Google Scholar 

  4. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694–701.

    Article  CAS  Google Scholar 

  5. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091–3102.

    Article  CAS  Google Scholar 

  6. Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997; 20: 843–846.

    Article  CAS  Google Scholar 

  7. Koscielniak E, Klingebiel TH, Peters C, Hermann J, Burdach ST, Bender-Gotze C et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19: 227–231.

    Article  CAS  Google Scholar 

  8. Hawkins D, Barnett T, Bensinger W, Gooley T, Sanders J . Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 2000; 34: 328–337.

    Article  CAS  Google Scholar 

  9. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Korholz D et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Ann Oncol 2000; 11: 1451–1462.

    Article  CAS  Google Scholar 

  10. Kushner BH, Meyers PA . How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001; 19: 870–880.

    Article  CAS  Google Scholar 

  11. Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewings sarcoma does not improve prognosis. J Clin Oncol 2001; 19: 2812–2820.

    Article  CAS  Google Scholar 

  12. Bertuzzi A, Castagna L, Nozza A, Quagliuolo V, Siracusano L, Balzarotti M et al. High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 2002; 20: 2181–2188.

    Article  CAS  Google Scholar 

  13. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993; 71: 1904–1922.

    Article  CAS  Google Scholar 

  14. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13: 610–630.

    Article  CAS  Google Scholar 

  15. Meza JL, Anderson J, Pappo AS, Meyer WH . Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 2006; 24: 3844–3851.

    Article  Google Scholar 

  16. Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000; 18: 4–11.

    Article  CAS  Google Scholar 

  17. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18: 3108–3114.

    Article  CAS  Google Scholar 

  18. Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W . Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer 2004; 42: 64–73.

    Article  CAS  Google Scholar 

  19. Hawkins WG, Hoos A, Antonescu CR, Urist MJ, Leung DH, Gold JS et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer 2001; 91: 794–803.

    Article  CAS  Google Scholar 

  20. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 2003; 98: 571–580.

    Article  Google Scholar 

  21. Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer 2002; 95: 377–388.

    Article  Google Scholar 

  22. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19: 1818–1829.

    Article  CAS  Google Scholar 

  23. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  24. Engelhardt M, Zeiser R, Ihorst G, Finke J, Muller CI . High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma. J Cancer Res Clin Oncol 2006; 133: 1–11.

    Article  Google Scholar 

  25. Laurence V, Pierga JY, Barthier S, Babinet A, Alapetite C, Palangie T et al. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am J Clin Oncol 2005; 28: 301–309.

    Article  CAS  Google Scholar 

  26. Dunst J, Ahrens S, Paulussen M, Rube C, Winkelmann W, Zoubek A et al. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int J Radiat Oncol Biol Phys 1998; 42: 379–384.

    Article  CAS  Google Scholar 

  27. Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A et al. Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 2001; 12: 1619–1630.

    Article  CAS  Google Scholar 

  28. Fuchs B, Valenzuela RG, Petersen IA, Arndt CA, Sim FH . Ewing's sarcoma and the development of secondary malignancies. Clin Orthop Relat Res 2003; 415: 82–89.

    Article  Google Scholar 

  29. Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l’Enfant. J Clin Oncol 2006; 24: 3997–4002.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. M Takahashi

    Present address: 3Current address: Division of Orthopaedic Oncology, Shizuoka Cancer Center Hospital, Naga-izumi, Shizuoka, Japan.,

  2. M Ogura

    Present address: 4Current address: Department of Hematology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.,

  3. Y Kagami

    Present address: 5Current address: Department of Hematology, Meitetsu Hospital, Nagoya, Japan.,

Authors and Affiliations

  1. Department of Orthopaedics, Aichi Cancer Center Hospital, Nagoya, Japan

    K Yamada, M Takahashi & H Sugiura

  2. Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan

    M Ogura, Y Kagami, H Taji, Y Kamiya & Y Morishima

Authors
  1. K Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Kagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Taji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Kamiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Yamada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamada, K., Takahashi, M., Ogura, M. et al. High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas. Bone Marrow Transplant 39, 471–476 (2007). https://doi.org/10.1038/sj.bmt.1705625

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705625

Keywords

This article is cited by

Search

Advanced search

Quick links